December 11
QLT Appoints Goldman, Sachs & Co. as Financial Advisor in Review of Strategic Options to Enhance Shareholder Value
PDF version
November 28
QLT Board Authorizes Exploration of Strategic Alternatives to Enhance Near- to Mid-Term shareholder Value
October 25
QLT Announces Q3 Results and Provides Guidance Update
October 18
QLT Completes Acquisition of Forsight Newco II, Inc.
QLT Announces Visudyne� Sales for Third Quarter and Provides Visudyne Sales Guidance for 2007
October 9
QLT Acquires Leading Edge Ocular Drug Delivery System From ForSight Labs
August 31
Eligard® Six-Month Formulation Successfully Completes European Approval Procedure
July 26
QLT Announces Q2 Results for 2007
July 23
QLT Announces FDA Filing and Review of Aczone™ Labeling Supplement for Removal of Blood Screening Requirement
July 17
QLT announces Visudyne Sales for the Second Quarter 2007
July 10
QLT Announces District Court Decision on Trial of Massachusetts Eye and Ear Infirmary Litigation
June 7
QLT Announces TSX Approval of US$50 Million Share Repurchase Program
June 4
QLT Announces US$50 Million Share Repurchase Program
May 29
QLT USA, Inc. Files Aczone™ Labeling Supplement for Removal of Blood Screening Requirement
May 17
QLT's Shareholders Elect Philip Livingston to the Board of Directors
April 30
QLT Strengthens its Expertise in Ocular by Adding David A. Saperstein M.D. as Interim Chief Medical Officer and Paul L. Kaufman M.D. as Head of the Ocular Scientific Advisory Board
April 25
QLT Announces that CHMP will Recommend to the European Commission that Occult Indication be Deleted from the Visudyne® Label in European Union
April 24
QLT announces Q1 Results for 2007
April 23
QLT Announces First Quarter 2007 Visuydne® Sales
March 5
QLT Settles MEEI Lawsuit with Respect to the '303 Patent
February 22
QLT Announces 2006 Results
February 9
QLT USA Signs Agreement with TAP to Settle United States Patent Litigation
January 18
QLT Announces Visudyne® Sales for Fourth Quarter and Fiscal Year 2006
January 3
QLT USA Receives Final Payment for Generic Dermatologyand Manufacturing Business
